This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TearLab Corporation Reports 2012 Financial Results

As of December 31, 2012, TearLab had $15.4 million in cash and cash equivalents.

"As demonstrated by our system order volumes for the fourth quarter, we had a very strong showing at the American Academy of Ophthalmology ("AAO") annual meeting in November," commented Elias Vamvakas, TearLab's Chief Executive Officer. "To help put that in perspective, 45% of total 2012 system orders came in the fourth quarter alone. While that sales performance was not fully reflected in our Q4-2012 financial results due to the lag between contract signing and product shipment, it is clear that we are starting to build a substantial recurring revenue base for the future."

Mr. Vamvakas continued, "Now, despite the absence of large events like AAO, growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of Dry Eye Disease has continued to drive positive momentum in the first quarter of 2013. Moving forward, we plan on continuing to execute our marketing strategy and to build our sales organization in order to help the groundbreaking TearLab® Osmolarity test grow to its full potential."

Conference Call and Webcast Information

TearLab will hold a conference call to discuss these results today, March 20, at 8:30am Eastern Time at 877-303-1593. The call will also be broadcast live and archived on TearLab's website at www.tearlab.com under the "webcasts" link in the Investor Relations section. For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (Toll free) 855-859-2056 or (Toll) 404-537-3406 and enter reservation #14510627 when prompted.

About TearLab Corporation

TearLab Corporation ( www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding our future recurring revenue expectations and our plans for executing our marketing strategy and building a salesforce, the future potential of the TearLab ® Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
TearLab Corp.
     
CONSOLIDATED STATEMENTS OF OPERATIONS (expressed in U.S. dollars except number of shares) ($ 000's)
     
  Three months ended December 31 Year ended December 31
   2012  2011  2012  2011
Revenue  $ 1,610  $ 499 $ 3,960  $ 2,124
Cost of goods sold  930 409  2,295  1,626
Gross profit  680 90  1,665  498
Operating expenses        
Amortization of intangible assets  304 304  1,215  1,215
General and administrative  1,140 1,100  4,770  3,842
Clinical, regulatory and research & development  618 542  2,241  1,304
Sales and marketing  1,942 865   5,471  2,195
Total operating expenses  4,004 2,811  13,697  8,556
Loss from operations  (3,324)  (2,721)  (12,032)  (8,058)
Other income (expenses) (328) (751)  (7,280)  (751)
Net loss (3,652) (3,472)  (19,312)  (8,809)
Weighted average number of shares outstanding – basic and diluted 28,607,209 20,414,993  25,490,186   17,744,736
Net loss per common share – basic and diluted  $ (0.13)  $ (0.17)  $ (0.76)  $ (0.50)
 
 
 
TearLab Corp.
     
CONSOLIDATED BALANCE SHEETS (expressed in U.S. dollars) ( $ 000's)
     
  December 31, 2012 December 31, 2011
     
ASSETS    
Current assets    
Cash and cash equivalents $ 15,437 $ 2,807
Accounts receivable, net 889 321
Inventory, net 1,863 898
Prepaid expenses 387 190
Other current assets 60 35
Total current assets 18,636 4,251
     
Fixed assets, net 630 199
Patents and trademarks, net 136 164
Intangible assets, net 4,709 5,924
Other non-current assets 28
Total assets $ 24,139 $ 10,538
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities    
Accounts payable $ 1,067 $ 218
Accrued liabilities 1,989 1,843
Obligations under warrants 6,239 2,957
Total current liabilities 9,295 5,018
     
     
Stockholders' equity    
Capital stock    
Preferred Stock, $0.001 par value, 10,000,000 authorized none outstanding
Common stock, $0.001 par value, 65,000,000 authorized, 28,741,653 issued and outstanding at December 31, 2012 and 40,000,000 authorized, 20,414,993 issued and outstanding at December 31, 2011 29 20
Additional paid-in capital 421,662 393,035
Accumulated deficit (406,847) (387,535)
Total stockholders' equity 14,844 5,520
Total liabilities and stockholders' equity $ 24,139 $ 10,538
CONTACT: Investors:
         Stephen Kilmer
         (905) 906-6908
         skilmer@tearlab.com
         
         Media:
         Leonard Zehr
         Managing Director
         Kilmer Lucas Inc.
         (905) 486-1158
         len@kilmerlucas.com

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs